To investigate the safety and therapeutic effectiveness of TACE combined with DynaCT-guided MWA for liver tumors ≤5 cm located in high-risk areas, defined as tumors near critical structures.
Key Findings:
All participants successfully underwent the combination treatment.
Adverse events were mostly grade 1 or 2, requiring minimal intervention.
Mean OS was 41.0 months (95% CI = 39.6–42.5) and mean PFS was 31.2 months (95% CI = 30.7–31.7).
Objective response rate (ORR) was 96.4% and disease control rate (DCR) was 98.2%.
Cumulative survival rates at 6, 12, 24, and 36 months were 98.1%, 94.5%, 85.4%, and 74.5%, respectively.
Interpretation:
TACE combined with DynaCT-guided MWA is a safe and effective treatment for liver tumors ≤5 cm in high-risk locations, showing promising survival outcomes compared to existing therapies.
Limitations:
Retrospective design may introduce selection bias and limit the strength of conclusions.
Small sample size limits generalizability.
Lack of long-term follow-up data.
Conclusion:
The combination of TACE and DynaCT-guided MWA presents a viable treatment option for patients with liver cancers ≤5 cm in high-risk locations, warranting further investigation to validate these findings.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
